The results of aflibercept treatment in patientswith naive diabetic macular edema: Areal world study Tedavi Olmamış Diabetik Makula Ödemi Olan Hastalarda Aflibercept Tedavisi: Gerçek Yaşam Verileri
Retina-Vitreus, cilt.28, sa.1, ss.67-72, 2020 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 28 Sayı: 1
- Basım Tarihi: 2020
- Dergi Adı: Retina-Vitreus
- Derginin Tarandığı İndeksler: Scopus, Academic Search Premier, EMBASE, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.67-72
- Anahtar Kelimeler: Aflibercept, Anti-VEGF, Diabetic macular edema
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Purpose: To present the long-term results of aflibercept treatment in treatment-naive patients with no diabetic macular edema (DME) in daily clinical practice. Method: This is a retrospective, single-center study designed to evaluate the functional and anatomic outcomes of intravitreal aflibercept treatment in patients with no previous treatment for DME. The patients included had DME defined by the loss of the foveal pit and central macular thickness (CMT) greater than 300 μm on OCT. Only patients who received at least 3 monthly (4 weeks) aflibercept (2 mg/0.05 cc) injections were included in the study. Retreatment was performed if a loss of best corrected visual acuity letters was BCVA) ≥5 between 2 consecutive visits or CMT worsened with CMT of >300 micron, or CMT increase by > 10%. Results: The mean BCVA (Logarithm of the minimum angle of resolution or recognition -logMAR) increased to 0.55±0.40 (0.1-2.0) after mean of 3.2±0.53 aflibercept injections (p= 0.001). At the final examination, mean visual acuity gain was 13.5±15.7 letters. At the final examination, gains in Early Treatment Diabetic Retinopathy Study (ETDRS) letters were documented in 44 eyes (69.8%), and visual acuity remained stable in 19 eyes (30%). The mean CMT was 430.8±135.39 μm (242-806) before aflibercept treatment (at baseline) and decreased to 303.6±57.7 μm (210-529) at the final examination (p= 0.0001). Conclusion: Aflibercept could be used as a first-line therapy in patients with treatment-naive DME. Clinicians could decrease the number of injections by using as-needed treatment regimen with a comparable improvement of visual acuity.